Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | CASP2 | P42575 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | NAAA | Q02083 | 1/20 | 0.52 |
| ▸ | RECQL | P46063 | 1/20 | 0.52 |
| ▸ | EPHX1 | P07099 | 5/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | FAAH | O00519 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9259257 | 0.97 | MEN1 (0.94) | MEN1KMT2ACASP2ALDH1A1SMN1; SMN2 | |
| SCHEMBL21765846 | 0.97 | MEN1 (0.94) | MEN1KMT2ACASP2ALDH1A1SMN1; SMN2 | |
| SCHEMBL11758762 | 0.97 | MEN1 (0.94) | MEN1KMT2ACASP2ALDH1A1SMN1; SMN2 | |
| SCHEMBL10101148 | 0.94 | MEN1 (0.89) | MEN1KMT2ACASP2ALDH1A1SMN1; SMN2 | |
| SCHEMBL718284 | 0.92 | MEN1 (0.85) | MEN1KMT2ACASP2NAAAEPHX1 | |
| SCHEMBL19556883 | 0.90 | MEN1 (0.81) | MEN1KMT2ACASP2ALDH1A1SMN1; SMN2 | |
| SCHEMBL4501660 | 0.90 | MEN1 (0.81) | MEN1KMT2ACASP2NAAAEPHX1 | |
| SCHEMBL10866272 | 0.90 | MEN1 (0.81) | MEN1KMT2ACASP2NAAAEPHX1 | |
| SCHEMBL8210316 | 0.90 | MEN1 (0.81) | MEN1KMT2ACASP2NAAAEPHX1 | |
| SCHEMBL8209020 | 0.90 | MEN1 (0.81) | MEN1KMT2ACASP2NAAAEPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210102185-A1 | Protein Macrocyclization | STICHTING VU (NL) | 2021-04-08 | — | — | US | disclosed |
| US-10669538-B2 | Templated molecules and methods for using such molecules | NUEVOLUTION A/S (DK) | 2020-06-02 | — | — | US | disclosed |
| WO-2020041270-A1 | COLLECTIONS OF PEPTIDES, PEPTIDE AGENTS, AND METHODS OF USE THEREOF | FOG PHARMACEUTICALS, INC. (US) | 2020-02-27 | — | — | WO | disclosed |
| US-20170198283-A1 | TEMPLATED MOLECULES AND METHODS FOR USING SUCH MOLECULES | NUEVOLUTION A/S (DK) | 2017-07-13 | — | — | US | disclosed |
| US-20170198283-A1 | TEMPLATED MOLECULES AND METHODS FOR USING SUCH MOLECULES | NUEVOLUTION A/S (DK) | 2017-07-13 | — | — | US | disclosed |
| US-9688980-B2 | Templated molecules and methods for using such molecules | NUEVOLUTION (DK) | 2017-06-27 | — | — | US | disclosed |
| US-20150315567-A1 | TEMPLATED MOLECULES AND METHODS FOR USING SUCH MOLECULES | NUEVOLUTION A/S (DK) | 2015-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10669538-B2 | Templated molecules and methods for using such molecules | ABL1, DHFR, TYMS | MEN1 1283/4885KMT2A 1686/4885CASP2 4130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.